J 2011

Clinical Relevance of uPA, uPAR, PAI 1 and PAI 2 Tissue Expression and Plasma PAI 1 Level in Colorectal Carcinoma Patients

HALÁMKOVÁ, Jana, Igor KISS, Zdeněk PAVLOVSKÝ, Jiří JARKOVSKÝ, Jiří TOMÁŠEK et. al.

Basic information

Original name

Clinical Relevance of uPA, uPAR, PAI 1 and PAI 2 Tissue Expression and Plasma PAI 1 Level in Colorectal Carcinoma Patients

Authors

HALÁMKOVÁ, Jana (203 Czech Republic, guarantor, belonging to the institution), Igor KISS (203 Czech Republic, belonging to the institution), Zdeněk PAVLOVSKÝ (203 Czech Republic, belonging to the institution), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Jiří TOMÁŠEK (203 Czech Republic, belonging to the institution), Štěpán TUČEK (203 Czech Republic, belonging to the institution), Lada HANAKOVA (203 Czech Republic), Mojmír MOULIS (203 Czech Republic, belonging to the institution), Zbyněk ČECH (203 Czech Republic, belonging to the institution), Jiřina ZAVŘELOVÁ (203 Czech Republic, belonging to the institution) and Miroslav PENKA (203 Czech Republic, belonging to the institution)

Edition

Hepatogastroenterology, 2011, 0172-6390

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30000 3. Medical and Health Sciences

Country of publisher

Germany

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 0.658

RIV identification code

RIV/00216224:14110/11:00055477

Organization unit

Faculty of Medicine

DOI

UT WoS

000300532700015

Keywords in English

Colorectal cancer; Plasminogen activator system; PAI 1; PAI 2; uPA; uPAR

Tags

International impact
Změněno: 9/2/2012 07:35, Mgr. Michal Petr

Abstract

V originále

Urokinase (uPA) is a serine protease, which together with uPAR, tPA, PAI 1 and PAI 2 forms the plasminogen activator system, a component of metastatic cascade contributing to the invasive growth and angiogenesis of malignant tumours. Methodology: Both preceding therapy and after 6-8 weeks of the treatment, plasma PAI 1 levels (photometric microplate method on the ELISA) and uPA, uPAR, PAI 1 and PAI 2 tissue expression (immunohistochemical reaction) were analysed from 80 colorectal carcinoma patients. Results: Analysis showed higher pre-treatment plasma levels of PAI 1 in patients with advanced tumours, which decreased after surgery or the start of therapy (p=0.004); Patients with higher plasma level PAI 1 before (0.013) and after therapy (0.004) had significantly shorter survival. There was a higher expression of uPA (p<0.001), uPAR (p<0.001), PAI 1 (p=0.042) and PAI 2 (p<0.001) in advanced colorectal carcinoma. A relationship between PAI 2 (p=0.010) and uPAR (p=0.019) expression and survival was demonstrated. There is a correlation between pre-treatment plasma PAI 1 levels and PAI 2 (p=0.028) and uPAR (p=0.043) expression. Conclusions: Immunohistochemical analysis of PAS in tumour tissue and plasma PAI 1 levels was found to be a useful prognostic factor in colorectal carcinoma patients. Plasma PAI 1 could be advantageous in evaluating the effectiveness of a mode of treatment.